Evaluation of the clinical efficacy and safety of perindopril 10 mg/indapamide 2.5 mg/amlodipine 5 or 10 mg/bisoprolol 5 mg in single-pill combination after 8 weeks of treatment versus the free combination of perindopril 10 mg, indapamide 2.5 mg and amlodipine 5 or 10 mg in patients with uncontrolled essential hypertension. An international, multicentre, randomised, double-blind, 16-week study.

Institut de Recherches Internationales Servier0 个研究点目标入组 968 人开始时间: 2021年11月22日最近更新: 2024年2月19日

适应症

试验速览

暂无简介。

•1. Essential hypertension in moderate to high cardiovascular risk patients treated with 3 antihypertensive drugs, including a diuretic, at the optimal tolerated doses for at least 1 month prior to the visit.
•2. Without change in antihypertensive therapy within the month prior to the visit.
•3. Office sitting SBP = 140 mmHg at selection visits.
•4. Patients for whom the addition of a beta-blocker is considered as the best therapeutic alternative according to the investigator.
•5. A recent (< 6 months) renal echography or Computerised Tomography scan (CT scan) or angiography without findings for secondary hypertension.
•6. Office sitting SBP = 140 mmHg at ASS2 and W000 visits.
•7. Mean ambulatory SBP = 135 mmHg at W000 visit over the real daytime period.
•8. 12-lead electrocardiogram (ECG) without any recent clinically significant abnormality.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 816
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 152

•1. Pregnant and lactating women
•2. No willing to refrain from consuming grapefruit and all beverages containing grapefruit during the study
•3. Contra-indications to treatment with perindopril, indapamide, amlodipine or bisoprolol
•4. Apparent or suspected secondary hypertension
•5. Any history or known severe disease likely to interfere with the conduct of the study or history of mental or psychiatric disorder
•6. Non-recovered pancreatic diseases
•7. Current treatment with beta-blockers. Past history of beta-blocker treatment is authorised assuming that beta-blockers have been stopped, according to each beta-blocker wash-out period, to avoid any rebound effect at the time of selection
•8. Current potassium supplementation
•9. Requirement for any treatment that may affect hypertension for reason other than to treat hypertension and which cannot be discontinued at selection
•10. Laboratory clinically significant abnormal values at ASS2 or W000 visit

发起方